More patients receiving panitumumab + FOLFOX@ versus FOLFOX@ had @ % ( @ % versus @ % ; P < @ ) or @ % ( @ % versus @ % ; P < @ ) TS at week @ ( early TS ) ; consistent TS benefits were observed over the first @weeks of treatment .